Literature DB >> 24382655

Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007.

Laia Alemany1, Silvia de Sanjosé, Sara Tous, Wim Quint, Carlos Vallejos, Hai-Rim Shin, Luis E Bravo, Patricia Alonso, Marcus A Lima, Núria Guimerà, Joellen Klaustermeier, Antonio Llombart-Bosch, Elena Kasamatsu, Silvio A Tatti, Ana Felix, Carla Molina, Julio Velasco, Belen Lloveras, Omar Clavero, Enrique Lerma, Jan Laco, Ignacio G Bravo, Rosa Guarch, Adela Pelayo, Jaume Ordi, Miguel Andújar, Gloria I Sanchez, Xavier Castellsagué, Nubia Muñoz, F Xavier Bosch.   

Abstract

Contribution over time of human papillomavirus (HPV) types in human cancers has been poorly documented. Such data is fundamental to measure current HPV vaccines impact in the years to come. We estimated the HPV type-specific distribution in a large international series of invasive cervical cancer (ICC) over 70 years prior to vaccination. Paraffin embedded ICC cases diagnosed between 1940 and 2007 were retrieved from eleven countries in Central-South America, Asia and Europe. Included countries reported to have low-medium cervical cancer screening uptake. Information on age at and year of diagnosis was collected from medical records. After histological confirmation, HPV DNA detection was performed by SPF-10/DEIA/LiPA25 (version1). Logistic regression models were used for estimating the adjusted relative contributions (RC) of HPV16 and of HPV18 over time. Among 4,771 HPV DNA positive ICC cases, HPV16 and HPV18 were the two most common HPVs in all the decades with no statistically significant variations of their adjusted-RC from 1940-59 to 2000-07 (HPV16-from 61.5 to 62.1%, and HPV18-from 6.9 to 7.2%). As well, the RC of other HPV types did not varied over time. In the stratified analysis by histology, HPV16 adjusted-RC significantly increased across decades in adenocarcinomas. Regarding age, cases associated to either HPV16, 18 or 45 were younger than those with other HPV types in all the evaluated decades. The observed stability on the HPV type distribution predicts a high and stable impact of HPV vaccination in reducing the cervical cancer burden in future vaccinated generations.
© 2013 UICC.

Entities:  

Keywords:  cervical cancer; human papillomavirus; time trends; types

Mesh:

Substances:

Year:  2013        PMID: 24382655     DOI: 10.1002/ijc.28636

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Human papillomavirus-16/18 AS04-adjuvanted vaccine (cervarix®): a guide to its two-dose schedule in girls aged 9-14 years in the EU.

Authors:  Katherine A Lyseng-Williamson
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

Review 2.  Chemotherapy and molecular therapy in cervical cancer.

Authors:  Gabriela Olivia Regalado Porras; Jessica Chávez Nogueda; Adela Poitevin Chacón
Journal:  Rep Pract Oncol Radiother       Date:  2018-09-27

3.  Trop2 gene: a novel target for cervical cancer treatment.

Authors:  Xiaoqi Liu; Siqi Li; Faping Yi
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-10       Impact factor: 4.553

4.  The presence of high-risk human papillomavirus (HPV) E6/E7 mRNA transcripts in a subset of sinonasal carcinomas is evidence of involvement of HPV in its etiopathogenesis.

Authors:  Jan Laco; Kateřina Sieglová; Hana Vošmiková; Pavel Dundr; Kristýna Němejcová; Jaroslav Michálek; Petr Čelakovský; Viktor Chrobok; Radovan Mottl; Alena Mottlová; Luboš Tuček; Radovan Slezák; Marcela Chmelařová; Igor Sirák; Milan Vošmik; Aleš Ryška
Journal:  Virchows Arch       Date:  2015-07-31       Impact factor: 4.064

5.  Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.

Authors:  Mathieu Boxus; Michel Fochesato; Agnès Miseur; Emmanuel Mertens; Najoua Dendouga; Sarah Brendle; Karla K Balogh; Neil D Christensen; Sandra L Giannini
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

6.  Distinctive distribution of HPV genotypes in cervical cancers in multi-ethnic Suriname: implications for prevention and vaccination.

Authors:  M G Grunberg; M Chan; M R Adhin
Journal:  Epidemiol Infect       Date:  2016-10-20       Impact factor: 4.434

7.  Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.

Authors:  Angela A Cleveland; Julia W Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Kayla Saadeh; Manideepthi Pemmaraju; Kyle Higgins; Sara Ehlers; Mary Scahill; Michelle L Johnson Jones; Troy Querec; Lauri E Markowitz; Elizabeth R Unger
Journal:  Int J Cancer       Date:  2019-05-06       Impact factor: 7.316

8.  Dominican Provider Attitudes Towards HPV Testing for Cervical Cancer Screening and, Current Challenges to Cervical Cancer Prevention in the Dominican Republic: a Mixed Methods Study.

Authors:  Erica Liebermann; Nancy Van Devanter; Natalia Frías Gúzman; Marilyn J Hammer; Danielle Ompad
Journal:  J Cancer Educ       Date:  2021-12       Impact factor: 1.771

Review 9.  Cancer prevention as part of precision medicine: 'plenty to be done'.

Authors:  Bernard W Stewart; Freddie Bray; David Forman; Hiroko Ohgaki; Kurt Straif; Andreas Ullrich; Christopher P Wild
Journal:  Carcinogenesis       Date:  2015-11-20       Impact factor: 4.944

10.  Control of cervical cancer in Peru: Current barriers and challenges for the future.

Authors:  Alfredo Aguilar; Joseph A Pinto; Jhajaira Araujo; Williams Fajardo; Leny Bravo; Luis Pinillos; Carlos Vallejos
Journal:  Mol Clin Oncol       Date:  2016-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.